Publications

Anchored screening identifies transcription factor blueprints underlying dendritic cell diversity and subset-specific anti-tumor immunity

In this paper, we demonstrate a systematic analysis of the ability of transcription factors to act as a genetic “toolbox” for determining dendritic cell identity, showing how different combinations reprogram specific subtypes with divergent functional properties that are capable of triggering tailored anti-tumor immune responses.

In vivo dendritic cell reprogramming for cancer immunotherapy

In this paper, we demonstrate key in vivo proof-of-concept data supporting our lead program, AT-108. Novel data shows that AT-108 reprograms tumor cells, directly within the immunosuppressed tumor microenvironment, into antigen-presenting dendritic cells. This causes strong, antigen-specific, anti-tumor responses to be mounted, resulting in durable tumor shrinkage even upon metastatic rechallenge.

Restoring Tumor Immunogenicity with Dendritic Cell Reprogramming

In this paper, we demonstrate reprogramming of over 60 mouse and human tumor cells across a broad spectrum of tumor types into functional antigen-presenting cells. This study represents a significant milestone for Asgard’s reprogramming technologies, providing the foundation for the ongoing development of its in-vivo engineering programs.

The paper was featured in the 'Research Highlights' section of Nature Immunology

Reprogramming Stars #6: A Venture Based in Cellular Reprogramming—An Interview with Dr. Cristiana Pires

In this interview, reprogramming Star Cristiana Pires unveils the career path that lead her to the stellar position of CEO and Co-founder at Asgard Therapeutics in this month issue of Cellular Reprogramming.

Single cell transcriptional profiling informs efficient reprogramming of human somatic cells to cross-presenting dendritic cells.

In this paper, we used single-cell transcriptomics to dissect successful reprogramming of human fibroblasts into induced cDC1-like cells and improved cDC1 reprogramming efficiency by 190-fold. We benchmarked the function of induced cDC1-like cells to naturally-occuring cDC1s and explored how PU.1, IRF8 and BATF3 engage the chromatin to induce the cDC1 fate in fibroblasts.